eFFECTOR Therapeutics Inc

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Zotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A)

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI) Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)

eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2023 BIO CEO & Investor Conference from February 6-9, 2023 in New York City, NY.

eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference

The stock price of eFFECTOR Therapeutics (EFTR) increased by 13.02% after hours in the most recent trading session. This is why.

EFTRWhy The eFFECTOR Therapeutics Stock Increased 13.02% After Hours (EFTR)

Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability

eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

- Key executive appointments: Douglas Warner, M.D., as CMO & Mayank Gandhi, M.D., as CBO –

eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO and REDWOOD CITY, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences:

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023 Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023

eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer. Dr. Gandhi will lead eFFECTOR's corporate growth strategy, business development and partnership opportunities.

eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET - - Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 -

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the upcoming H.C. Wainwright 24 th Annual Global Investment Conference.

eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial

eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced it has appointed Douglas Warner, M.D., as chief medical officer. Dr. Warner will develop strategies to continue advancing eFFECTOR's two clinical-stage STRIs into advanced and potentially registrational trials.

eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer

Nexgel

Invacare

TRACON Pharmaceuticals

U.S. crude oil futures traded higher by over 1% on Tuesday. Investors, meanwhile, focused on some notable insider trades.

4 Stocks Under $2 Insiders Are Aggressively Buying: NEXGEL, eFFECTOR Therapeutics And More

SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference.

eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

Two partial responses observed in heavily pre-treated ER+ breast cancer patients

eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Positive initial data demonstrated pharmacologically relevant exposures

eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting

Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial

eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Premal Patel, M.D., Ph.D., chief medical officer, has resigned to pursue a new career opportunity

eFFECTOR Therapeutics Announces Transition in Clinical Leadership

SAN DIEGO and REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2021, and provided a corporate update.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SAN DIEGO and REDWOOD CITY, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Kristen Harrington-Smith, Senior Vice President & Chief Commercial Officer at ImmunoGen, to the company's board of directors. Concurrent with Ms. Harrington-Smith's appointment, Jonathan Root, M.D., has resigned from the company's board of directors.

eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at the 2022 BIO CEO & Investor Conference.

eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 ≥1% patient population, representing additional $5 billion U.S. market opportunity

eFFECTOR Therapeutics Provides Pipeline and Business Updates

Study Demonstrates Role of Zotatifin in Blocking Tumor Growth in Receptor Tyrosine Kinase Driven Tumors Study Demonstrates Role of Zotatifin in Blocking Tumor Growth in Receptor Tyrosine Kinase Driven Tumors

News for eFFECTOR Therapeutics Inc Stock (EFTR)